Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mianbo Wang

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
International Journal of Rheumatic Diseases|October 9, 2025
The PROMIS-29 and SF-36 Quality of Life Scales Are Not Interchangeable in Systemic SclerosisMurray Baron, Charmaine van Eeden, Mohamed Osman, et al.
Arthritis Research & Therapy|June 7, 2020
Immunosuppressive treatment in diffuse cutaneous systemic sclerosis is associated with an improved composite response index (CRISS)Boyang Zheng, Marie Hudson, Mianbo Wang, et al.
Journal of Scleroderma and Related Disorders|June 8, 2023
Occupation as a gendered-role and outcome in systemic sclerosisFatema Alkhamees, Oriana Hoi Yun Yu, Mianbo Wang, et al.
Journal of Scleroderma and Related Disorders|April 6, 2022
Interstitial lung disease is associated with an increased risk of lung cancer in systemic sclerosis: Longitudinal data from the Canadian Scleroderma Research GroupLama Sakr, Marie Hudson, Mianbo Wang, et al.
Journal of Scleroderma and Related Disorders|April 7, 2022
NT-proBNP, hs-cTnT, and CRP predict the risk of cardiopulmonary outcomes in systemic sclerosis: Findings from the Canadian Scleroderma Research GroupMayank Jha, Mianbo Wang, Russell Steele, et al.
Seminars in Arthritis and Rheumatism|May 12, 2015
Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expectNeha Srivastava, Marie Hudson, Solène Tatibouet, et al.
Rheumatology (Oxford, England)|October 2, 2021
Association between autoantibodies in systemic sclerosis and cancer in a national registrySabrina Hoa, Selma Lazizi, Murray Baron, et al.
Seminars in Arthritis and Rheumatism|February 12, 2022
Associations between the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS), survival and other disease measuresBoyang Zheng, Mianbo Wang, Wendy Stevens, et al.
Journal of Scleroderma and Related Disorders|March 31, 2025
The minimal clinically important difference of the scleroderma clinical trials consortium damage indexMurray Baron, Dylan Hansen, Susanna Proudman, et al.
Arthritis Care & Research|November 14, 2024
Immunosuppressive Drugs in Early Systemic Sclerosis and Prevention of Damage AccrualMurray Baron, Mandana Nikpour, Dylan Hansen, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
International Journal of Rheumatic Diseases|October 9, 2025
The PROMIS-29 and SF-36 Quality of Life Scales Are Not Interchangeable in Systemic SclerosisMurray Baron, Charmaine van Eeden, Mohamed Osman, et al.
Arthritis Research & Therapy|June 7, 2020
Immunosuppressive treatment in diffuse cutaneous systemic sclerosis is associated with an improved composite response index (CRISS)Boyang Zheng, Marie Hudson, Mianbo Wang, et al.
Journal of Scleroderma and Related Disorders|June 8, 2023
Occupation as a gendered-role and outcome in systemic sclerosisFatema Alkhamees, Oriana Hoi Yun Yu, Mianbo Wang, et al.
Journal of Scleroderma and Related Disorders|April 6, 2022
Interstitial lung disease is associated with an increased risk of lung cancer in systemic sclerosis: Longitudinal data from the Canadian Scleroderma Research GroupLama Sakr, Marie Hudson, Mianbo Wang, et al.
Journal of Scleroderma and Related Disorders|April 7, 2022
NT-proBNP, hs-cTnT, and CRP predict the risk of cardiopulmonary outcomes in systemic sclerosis: Findings from the Canadian Scleroderma Research GroupMayank Jha, Mianbo Wang, Russell Steele, et al.
Seminars in Arthritis and Rheumatism|May 12, 2015
Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expectNeha Srivastava, Marie Hudson, Solène Tatibouet, et al.
Rheumatology (Oxford, England)|October 2, 2021
Association between autoantibodies in systemic sclerosis and cancer in a national registrySabrina Hoa, Selma Lazizi, Murray Baron, et al.
Seminars in Arthritis and Rheumatism|February 12, 2022
Associations between the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS), survival and other disease measuresBoyang Zheng, Mianbo Wang, Wendy Stevens, et al.
Journal of Scleroderma and Related Disorders|March 31, 2025
The minimal clinically important difference of the scleroderma clinical trials consortium damage indexMurray Baron, Dylan Hansen, Susanna Proudman, et al.
Arthritis Care & Research|November 14, 2024
Immunosuppressive Drugs in Early Systemic Sclerosis and Prevention of Damage AccrualMurray Baron, Mandana Nikpour, Dylan Hansen, et al.
Pageof 4